Delcath Systems (DCTH) vs TriSalus Life Sciences (TLSI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Delcath Systems (DCTH) has outperformed TriSalus Life Sciences (TLSI) over the past year, gaining 35.5% versus a loss of 14.8%. Over five years, DCTH leads with a +59.8% price change compared with -58.3% for TLSI. Delcath Systems is the larger company by market cap ($533.0 million vs $250.0 million), about 2.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DCTH | TLSI |
|---|---|---|
| Share price | $15.36 | $4.06 |
| Market cap | $532.97M | $249.99M |
| 1-day change | +2.13% | -1.69% |
| YTD return | +48.91% | -40.83% |
| 1-year return | +35.50% | -14.85% |
| 5-year return | +59.83% | -58.28% |
| Forward P/E | 341.33 | — |
| EPS (TTM) | $0.01 | $-1.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.42 | $7.95 |
| 52-week low | $8.12 | $2.20 |
| Distance from 52-week high | -11.83% | -48.93% |
| Analyst consensus | none | none |
| Avg. price target upside | +56.25% | +156.16% |
| Average volume | 479.73K | 275.38K |
| Shares outstanding | 34.70M | 61.57M |
| Employees | 156 | 102 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Delcath Systems is about 2.1 times larger than TriSalus Life Sciences by market value ($532.97M vs $249.99M).
- DCTH has outperformed TLSI by 50.3 percentage points over the past year.
About Delcath Systems
DCTH stock →Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Health Care · Medical/Dental Instruments · 156 employees
About TriSalus Life Sciences
TLSI stock →TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States.
Health Care · Medical Specialities · 102 employees
DCTH vs TLSI FAQ
Which is bigger, Delcath Systems or TriSalus Life Sciences?
Delcath Systems (DCTH) is larger, with a market capitalization of $532.97M compared with $249.99M for TriSalus Life Sciences (TLSI).
Which stock has performed better over the past year, DCTH or TLSI?
DCTH returned +35.50% over the past 12 months, compared with -14.85% for TLSI (price return, excluding dividends). Past performance does not predict future results.
Are Delcath Systems and TriSalus Life Sciences in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for Delcath Systems and Medical Specialities for TriSalus Life Sciences.